- Home
- RARE vs ALKT Comparison
RARE vs ALKT Comparison
Compare RARE & ALKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- ALKT
- Stock Information
- Founded
- RARE 2010
- ALKT 2007
- Country
- RARE United States
- ALKT United States
- Employees
- RARE N/A
- ALKT N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- ALKT EDP Services
- Sector
- RARE Health Care
- ALKT Technology
- Exchange
- RARE Nasdaq
- ALKT Nasdaq
- Market Cap
- RARE 3.3B
- ALKT 3.1B
- IPO Year
- RARE 2014
- ALKT 2021
- Fundamental
- Price
- RARE $37.17
- ALKT $30.46
- Analyst Decision
- RARE Strong Buy
- ALKT Buy
- Analyst Count
- RARE 17
- ALKT 8
- Target Price
- RARE $92.29
- ALKT $39.88
- AVG Volume (30 Days)
- RARE 974.0K
- ALKT 868.5K
- Earning Date
- RARE 07-31-2025
- ALKT 07-30-2025
- Dividend Yield
- RARE N/A
- ALKT N/A
- EPS Growth
- RARE N/A
- ALKT N/A
- EPS
- RARE N/A
- ALKT N/A
- Revenue
- RARE $590,689,000.00
- ALKT $355,557,000.00
- Revenue This Year
- RARE $18.94
- ALKT $36.09
- Revenue Next Year
- RARE $28.93
- ALKT $24.79
- P/E Ratio
- RARE N/A
- ALKT N/A
- Revenue Growth
- RARE 33.46
- ALKT 26.55
- 52 Week Low
- RARE $29.59
- ALKT $21.70
- 52 Week High
- RARE $60.37
- ALKT $42.29
- Technical
- Relative Strength Index (RSI)
- RARE 55.64
- ALKT 62.69
- Support Level
- RARE $35.73
- ALKT $28.05
- Resistance Level
- RARE $36.22
- ALKT $31.13
- Average True Range (ATR)
- RARE 1.37
- ALKT 0.84
- MACD
- RARE 0.25
- ALKT -0.04
- Stochastic Oscillator
- RARE 90.54
- ALKT 77.00
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About ALKT Alkami Technology Inc.
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company's solution, the Alkami Digital Banking Platform, allows FIs to onboard and engage new users, accelerate revenues and meaningfully improve operational efficiency, all with the support of a proprietary, true cloud-based, multi-tenant architecture.